Blog: Research

Research shows hot chocolate could help reduce fatigue

6 March 2019

Source MS Society: We know around 90% of people with MS experience fatigue, which can severely impact their quality of life.

Innovative clinical research using robotic technology to improve balance & mobility for people living with MS

4 March 2019

A ground-breaking clinical research trial is inviting people living with Multiple Sclerosis (MS) to take part in the evaluation of a balance exercise program using a robotic walking device.

Continuous Use of Gilenya for Up to 3 Years Can Lead to 50% Drop in Annual Relapse Rates, Real-world Study Says

15 February 2019

Source Multiple Sclerosis News Today: Multiple sclerosis (MS) patients who began treatment with Gilenya (fingolimod) and stayed with it continuously showed a more than 50 percent reduction in annual relapse rates, a real-world study following these people for up to three years found.

Masterswitch discovered in body's immune system

12 February 2019

Source Science Daily: Scientists have discovered a critical part of the body's immune system with potentially major implications for the treatment of some of the most devastating diseases affecting humans.

The iStep MS Trial research team invite you to a free seminar at Brunel University on Saturday 23rd February.

7 February 2019

An invitation from the iStep-MS Trial Research Team: We would like to invite you to a free seminar at Brunel University London on Saturday 23rd February where we will share findings from the iStep-MS trial.

Cochrane Review of effectiveness of exercise to prevent falls

6 February 2019

Source Independent Living: Exercise is frequently cited as a good way of helping to prevent falls, and now we have strong evidence that a programme of exercise can indeed prevent falls amongst older people living in the community.

Letter calls for ocrelizumab to be made available for people with PPMS

6 February 2019

Source MS Trust: A letter signed by the MS Society, MS Trust, Shift MS and leading neurologists calls on NICE, NHS England and drug manufacturer Roche to make ocrelizumab available for people with primary progressive MS.

Back in September, NICE announced that it would not be recommending ocrelizumab as an NHS treatment for early primary progressive MS. This decision was met with anger and dismay from people with MS and MS charities, and the MS Society started a petition, calling for...

Brain Cells Key to Myelin Grown in Lab and Show Long-Term Survival Essential to Research, Study Reports

6 February 2019

Source Multiple Sclerosis News Today: Stem cells tweaked in the laboratory have allowed researchers, reportedly for a first time, to generate and maintain ball-shaped cultures — called spheroids — of human brain cells in 3D that contain oligodendrocytes, the cells that produce myelin, along with neurons and the astrocytes that are essential to nerve cell health.

These long-surviving spheroids (which the researchers call “human oligodendrocyte spheroids”) will help scientists in...

Disease modifying drugs may reduce risk of secondary progressive MS

21 January 2019

Source MS Trust: People with relapsing remitting MS starting early treatment with a disease modifying drug have a lower risk of developing secondary progressive MS, according to a study of medical records.

Rituximab beneficial in secondary progressive MS

16 January 2019

Source Medicalxpress: For patients with secondary progressive multiple sclerosis (SPMS), treatment with rituximab is associated with a significantly lower Expanded Disability Status Scale (EDSS) score and delayed progression, according to a study published online Jan. 7 in JAMA Neurology.

Yvonne Naegelin, M.D., from the University of Basel in Switzerland, and colleagues conducted a retrospective cohort study using data from patients with SPMS at three multiple sclerosis centers from...

Pages

Category

Archive